Latest Breaking News On - ஒற்றை ஏறுதல் டோஸ் - Page 1 : vimarsana.com
4 Trending Biotech Stocks To Watch This Week
dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
(KYMR) - Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Operator
Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today s recorded presentation all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead Vince.
Vincent Anzalone
Vice President of Investor Relations
Thank you, Jessi. Good afternoon everyone. Thank you for joining us today to discuss Arrowhead s results for it s Fiscal 2021 Second Quarter ended March 31, 2021. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our pipeline; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, James Hassard, our Chief Commercial Officer, and Dr. James Hamilto
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
ASLAN PHARMACEUTICALS LIMITEDMay 5, 2021 GMT
- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021
SINGAPORE, May 05, 2021 (GLOBE NEWSWIRE) ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on ASLAN004 has been accepted for poster presentation at the upcoming 2021 Society for Investigative Dermatology (SID) virtual meeting between 3-8 May, 2021. The data is available to view during the Pharmacology and Drug Development segment on 6 May, 2.30pm to 4pm EST, and will be published in the fall edition of the Journal of Investigative Dermatology.